| Trial ID: | L0121 |
| Source ID: | NCT02289235
|
| Associated Drug: |
Ginger
|
| Title: |
Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM
|
| Acronym: |
GinLivDM
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Fatty Liver|Diabetes Mellitus, Type 2
|
| Interventions: |
Drug: Ginger|Drug: Placebo
|
| Outcome Measures: |
Change in ALT (liver transaminases) level|Change in score of fatty liver in fibroscan|Change in AST (liver transaminases) level|Change in Gama GT (??-glutamyl transpeptidase) levels|Number of patients with adverse events
|
| Sponsor/Collaborators: |
Shiraz University of Medical Sciences
|
| Gender: |
All
|
| Age: |
20 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Early Phase 1
|
| Enrollment: |
76
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
May 1, 2019
|
| Completion Date: |
February 1, 2020
|
| Results First Posted: |
--
|
| Last Update Posted: |
October 20, 2020
|
| Locations: |
Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of
|
| URL: |
https://ClinicalTrials.gov/show/NCT02289235
|
